ICH E2D(R1) brings renewed attention to how organizations identify, assess and oversee safety information generated outside traditional pharmacovigilance channels. Explore key governance considerations and how to assess whether your current framework is ready.
In this free guide, we break down the most critical updates to ICH E6(R3)—and provide practical, inspection-ready strategies to help you stay compliant, audit-ready, and ahead of regulatory expectations.
In this free guide, we break down the most critical updates to ICH E6(R3)—and provide practical, inspection-ready strategies to help you stay compliant, audit-ready, and ahead of regulatory expectations.
Discover how ADAMAS secured a multi-year GxP partnership with a global biopharma company.
Discover how ADAMAS rebuilt momentum with a returning biopharma client through consistent engagement and delivery.
Discover how ADAMAS turned a single GxP enquiry into a multi-year quality partnership.
Watch the full on-demand session and gain practical insights into designing risk-based QA oversight under ICH E6 (R3).
Learn how analytics and early QA engagement help restore control and regulatory confidence.
ADAMAS Consulting’s cutting-edge system incorporating automated risk algorithm technology, defining a new standard for Pharmacovigilance Risk Assessment
In this free guide, we break down the most critical updates to ICH E6(R3)—and provide practical, inspection-ready strategies to help you stay compliant, audit-ready, and ahead of regulatory expectations.
From Reactive Compliance to Strategic Partnership: How Clinical Quality Is Evolving
RQA 8th Global QA Conference 2026 | London, UK
FDA’s Real-Time Clinical Trial Initiative: Endorses Data-Enabled QA Oversight
SCOPE Europe 2026 | Barcelona, Spain
Beyond Audit Cycles: A Risk-Based Approach to Regulatory Excellence in Pharmacovigilance